[{"orgOrder":0,"company":"Remix Therapeutics","sponsor":"Foresite Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Financing","leadProduct":"RNA processing targeted therapeutics","moa":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Remix Therapeutics","amount2":0.080000000000000002,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0.080000000000000002,"dosageForm":"Oral","sponsorNew":"Remix Therapeutics \/ Foresite Capital","highestDevelopmentStatusID":"1","companyTruncated":"Remix Therapeutics \/ Foresite Capital"},{"orgOrder":0,"company":"Remix Therapeutics","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Remix Therapeutics","amount2":1.05,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":1.05,"dosageForm":"","sponsorNew":"Remix Therapeutics \/ Janssen Pharmaceutical","highestDevelopmentStatusID":"3","companyTruncated":"Remix Therapeutics \/ Janssen Pharmaceutical"},{"orgOrder":0,"company":"Remix Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Remix Therapeutics","amount2":1.04,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":1.04,"dosageForm":"","sponsorNew":"Remix Therapeutics \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"3","companyTruncated":"Remix Therapeutics \/ F. Hoffmann-La Roche"}]

Find Clinical Drug Pipeline Developments & Deals by Remix Therapeutics

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Compamed
                          Not Confirmed
                          Compamed
                          Not Confirmed

                          Details : Roche will use Remix's REMaster platform to develop small molecule therapeutics modulating RNA processing, securing exclusive rights to specific targets.

                          Brand Name : Undisclosed

                          Molecule Type : Small molecule

                          Upfront Cash : $30.0 million

                          January 03, 2024

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Oncology

                          Highest Development Status : Discovery Platform

                          Sponsor : F. Hoffmann-La Roche

                          Deal Size : $1,042.0 million

                          Deal Type : Collaboration

                          blank

                          02

                          Compamed
                          Not Confirmed
                          Compamed
                          Not Confirmed

                          Details : Under the terms of the agreement, Remix will receive preclinical, clinical, commercial, and sales milestone payments and tiered royalties for products. In exchange, Janssen will have exclusive rights to three specific targets with applications in immunol...

                          Brand Name : Undisclosed

                          Molecule Type : Small molecule

                          Upfront Cash : $45.0 million

                          February 17, 2022

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Immunology

                          Highest Development Status : Discovery Platform

                          Sponsor : Johnson & Johnson Innovative Medicine

                          Deal Size : $1,045.0 million

                          Deal Type : Collaboration

                          blank

                          03

                          Compamed
                          Not Confirmed
                          Compamed
                          Not Confirmed

                          Details : The funds will support development of the company’s REMaster technology platform and advancement of a pipeline of RNA processing targeted therapeutics.

                          Brand Name : Undisclosed

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          December 08, 2020

                          Lead Product(s) : RNA processing targeted therapeutics

                          Therapeutic Area : Oncology

                          Highest Development Status : Undisclosed

                          Sponsor : Foresite Capital

                          Deal Size : $81.0 million

                          Deal Type : Financing

                          blank